levofloxacin has been researched along with diphenhydramine in 16 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (diphenhydramine) | Trials (diphenhydramine) | Recent Studies (post-2010) (diphenhydramine) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 4,146 | 415 | 542 |
| Protein | Taxonomy | levofloxacin (IC50) | diphenhydramine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.98 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 3.542 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 1.05 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.372 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.162 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.346 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.647 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 3.542 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 1.295 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.98 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.171 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 1.118 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 3.8852 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Keserü, GM | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Antonsson, M; Bengtsson, O; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Jerndal, G; Wan, H; Winiwarter, S | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Gozalbes, R; Pineda-Lucena, A | 1 |
| Ahlin, G; Bergström, F; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Rehngren, M; Wan, H | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kato, M; Takayama, S; Yoshida, M | 1 |
| Ishiwata, Y; Itoga, Y; Yasuhara, M | 1 |
| Areej, S; Javeed, A; Raza, S; Sattar, A | 1 |
1 review(s) available for levofloxacin and diphenhydramine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
15 other study(ies) available for levofloxacin and diphenhydramine
| Article | Year |
|---|---|
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
Topics: Animals; Blood-Brain Barrier; Brain; Extracellular Fluid; Humans; Linear Models; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
Topics: Animals; Biological Transport; Brain; Chemical Phenomena; Dialysis; Hydrogen-Ion Concentration; In Vitro Techniques; Lysosomes; Male; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tissue Distribution | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Effect of levofloxacin and ciprofloxacin injection on permeability of the tail vein in mice and skin microvasculature in rats.
Topics: Animals; Anti-Infective Agents; Capillary Permeability; Ciprofloxacin; Diphenhydramine; Hydrogen-Ion Concentration; Injections, Intravenous; Levofloxacin; Male; Mast Cells; Mice; Mice, Inbred BALB C; Microcirculation; Ofloxacin; Osmolar Concentration; Rats; Rats, Sprague-Dawley; Skin; Tail; Veins | 1994 |
Effect of levofloxacin on serum glucose concentration in rats.
Topics: Adrenal Medulla; Animals; Anti-Bacterial Agents; Blood Glucose; Diphenhydramine; Dose-Response Relationship, Drug; Epinephrine; Histamine; Histamine H1 Antagonists; Histamine Release; Hyperglycemia; Hypoglycemia; In Vitro Techniques; Insulin; Levofloxacin; Male; Ofloxacin; Rats; Rats, Wistar; Time Factors | 2006 |
Diphenhydramine and levofloxacin combination therapy against antimicrobial resistance in respiratory tract infections.
Topics: Animals; Anti-Bacterial Agents; Cell Line; Cell Survival; Cricetinae; Diphenhydramine; Drug Resistance, Bacterial; Drug Synergism; Humans; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Respiratory Tract Infections | 2021 |